Workers at an Onyx Pharmaceuticals facility in South San Francisco filed out of the building and into a parking lot Wednesday afternoon after employees reported smelling gas.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.
Amgen's cancer vaccine candidate may be awaiting FDA and EMA approval as a melanoma monotherapy, but like many of its peers, it's also looking to explore its prospect's potential as part of an immunotherapy duo, and now it's kicked off a trial combining its treatment with Merck's anti-PD-1 therapy that should help it do just that.
Good news for Amgen and its quest to gain a multiple myeloma edge over Celgene's Pomalyst: Results are out from a Phase III Kyprolis trial in patients with relapsed forms of the disease--and investigators say they could crown a new standard of care.
Amgen and Merck have launched an early-stage trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer.
Fundamental scientific and patient advances, as well as the investors who embrace them, have transformed biotech in just the last few years. As this has coincided with a broader resurgence in the stock market, industry valuations have skyrocketed. Suddenly, big cap biotechs Gilead Sciences and Amgen are larger than all but four of their pharma peers as measured by market cap.
About 1.5 million Americans suffer from familial hypercholesterolemia, an inherited disease that leads to dangerously high cholesterol, and they're likely to be the first targets for a new class of drugs that promise to bring in blockbuster sales.
The FDA approved Amgen's new leukemia treatment more than 5 months ahead of schedule, green-lighting the first contender among a new class of immunotherapies that promise to change the standard of care in blood cancer.
In biotech, here are the top 10 news stories of the year so far, based on web traffic.
Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.